

COVID-19 Serology Control Panel (CSCP)

W. Jon Windsor, MLS (ASCP), MPH

May C. Chu, PhD




BILL & MELINDA
GATES foundation

How this came about (March 2020):

- No coordinated infrastructure exists that allows for access to quality serological reference materials
- At least 145 COVID-19 antibody test kits were listed for with no quick way to assess their quality (the list grew to over 400)
- Diagnostic test unreliability in general was leading to deterioration of trust in the results
- Recognize the need to improve and maintain quality laboratory test

Guiding Principles

- Equitable access and fairness - Providing equal access to all regions, both public and private testing facilities, for the improvement of COVID-19 serological testing
- Collaboration and support – Working with organizations and institutions to support a global resource for quality COVID-19 serological testing
- Transparency and sharing – Sharing of information and protocols for better understanding and improvements to the quality of COVID-19 testing
- Sustainability and country ownership – Create a virtual biorepository and to transfer technology to countries and organizations to bring access to quality materials



A conceptual design of a more sustainable and enduring infrastructure

Objectives

- ▶ Provide a quick overview of the CSCP.
- ▶ Define the process used to develop the CSCP.
- ▶ Discuss the validation of the CSCP.
 - ▶ Share preliminary findings
- ▶ Discuss our current standing and next steps.

Overview

- ▶ The CSCP is a kit of 5 well characterized and validated Dried Tube Specimens for labs to use as a resource to:
 - ▶ COVID-19 Serology Test Comparisons
 - ▶ Quality Control
 - ▶ Training Material
 - ▶ Multi-Center Research Studies
- ▶ **Goal:** Track the performance of COVID-19 serology diagnostic tests for quality and consistency.

What are Dried Tube Specimens (DTS)?




Fig. 1. Schematic of DTS preparation and testing.

Benefits of DTS

- ▶ Kit is stable at a wider temperature range.
 - ▶ ~1 month between -20C and 37C
- ▶ Simplifies sample transport and storage logistics as there is no cold chain requirement



CSCP Development & Design



CSCP Evaluation Group

Lab 1

Method(s) used:
ELISA
HE-ELISA

Antibody(s):
IgM
IgG

Antigen(s):
Nucleocapsid

Lab 2

Method(s) used:
ELISA

Antibody(s):
IgG

Antigen(s):
Nucleocapsid
Receptor Binding Domain

Lab 3

Method(s) used:
Focus-Reduction
Neutralization Test

Antibody(s):
Total Ig

Antigen(s):
Total Virus

Lab 4

Method(s) used:
Pseudo-Virion
Neutralization Assay

Antibody(s):
Total Ig

Antigen(s):
Spike


Lab 5

Method(s) used:
Nano-bead
microarray

Antibody(s):
IgG

Antigen(s):
Nucleocapsid
Receptor Binding Domain


- Our results so far represent a small number of tests being deployed in research and diagnostic testing, but mirrors the types of platforms being used




Plasma Pooling Results

The background of the slide is a deep blue color with several stylized, glowing virus particles scattered across it. A dark blue horizontal bar spans the width of the slide, containing the title text. The virus particles are rendered with a textured, spiky surface, resembling coronaviruses, and have a slight glow.


Lab 1 ELISA: High vs Medium/Low Positive Pooled Plasma Results



Lab 2 ELISA: High vs Medium/Low Positive Pooled Plasma Results




Lab 3 FRNT: High vs Medium/Low Positive Pooled Plasma Results




Liquid vs Dried Tube Specimen (DTS) Comparison

- Compared using the Epitope Diagnostics COVID-19 serology platform.
- DTS undergo 1:10 dilution during rehydration step.
- Liquid specimen comparable to DTS

Medium/Low Positive Pools: DTS vs Liquid Reactivity




High Positive Pools: DTS vs Liquid Reactivity



| | OD values |
|------------------|-----------|
| Positive Cut-off | 0.29 |
| Negative Cutoff | 0.24 |

Long Term Stability Results


-20C Long Term Stability Results



Ambient Temperature (22-25C) Long Term Stability



37C Long Term Stability



Example CSCP User Result Form

COVID-19 Serology Control Panel (CSCP) User Result Report

| | |
|-----------------------|---|
| Institution | Your Lab |
| Point of Contact | Jan Windsor |
| Your Assigned User ID | CSCPUSER0001 |
| Serology Test Format | Enzyme Linked Immunosorbent Assay (ELISA) |
| Serology Platform | Laboratory Developed Test |
| CSCP Kit # | CSCPKIT0001 |
| Report Date | 15Oct2020 |









| | Sample ID | CSCP result | User Result | Interpretation |
|-----------|-----------|-------------|-------------|----------------|
| Sample 1: | CP140642 | | | INCORRECT |
| Sample 2: | CP140642 | | | CORRECT |
| Sample 3: | CP140715 | | | CORRECT |
| Sample 4: | CP140672 | | | INCORRECT |
| Sample 5: | CP140735 | | | CORRECT |




| Control | Result | Interpretation | Meaning |
|---------|--------|--|--|
| | | Your serology test agreed with expected reactivity | Performance compatible with expected results |
| | | Medium level antibody was not detected during testing | May indicate sensitivity limit of test platform is lower than expected |
| | | 1 of 2 identical medium level antibody agreed with expected reactivity | |
| | | 1 of 2 identical negative results did not agree with expected reactivity | May indicate test performance or reconstitution error |
| | | Your serology test does not agree with expected reactivity | Suggest that reconstitution of kit was problematic |



If you have any questions or concerns, please email us at: CSCPuser@billmeln.org




| Correct | Incorrect | Interpretation | Meaning |
|--|---|--|--|
|  | | Your serology test agreed with expected reactivity | Performance compatible with expected results |
|  |  | Medium level antibody was not detected during testing | May indicate sensitivity level of test platform is lower than expected |
|  |  | 1 of 2 identical Medium level antibody agreed with expected reactivity | |
|  |  | 1 of 2 identical Negative results did not agree with expected reactivity | May indicate test performance or reconstitution error |
| |  | Your serology test does not agree with expected reactivity | Suggest that reconstitution of DTS was problematic |

| Key | |
|---|-----------------|
|  | Strong Positive |
|  | Weak Positive |
|  | Negative |

Current Status of the COVID-19 Serology Control Panel

- ▶ We have launched for Users
- ▶ If Interested, follow the instructions→
- ▶ Or visit the following link to request a kit for your lab:
https://docs.google.com/forms/d/e/1FAIpQLSdLHPMGINTJgdrkp2BqISx3Dfzkar0nW4wvGroOoGcF_WO8sw/viewform
- ▶ The University of Colorado Center for Global Health website:
<https://coloradosph.cuanschutz.edu/research-and-practice/centers-programs/globalhealth/research-projects/global-infectious-disease-consortium/home>



Here is what a CSCP Kit looks like

Assembled



Disassembled



CSCP Status & Next Steps

CSCP User Results So Far...

Strong Positive



Medium/Low Positive



■ Correct ■ Incorrect


Negative



Next steps:

- ▶ Continuous accretion and analysis of CSCP kit results.
 - ▶ Test in parallel with other standards (including NIBSC International Standards)
- ▶ Embed CSCP kits as part of lateral flow test kits being rolled out in African region
 - ▶ Coordinating with grassroots labs
- ▶ Creating other screening panels: Zika, dengue
- ▶ Launch a virtual biorepository as a global good infrastructure
 - ▶ Hub: Virtual Biorespository, <https://globalbiorepository.tghn.org/>

Questions?



Contact Information:

May Chu: May.Chu@cuanschutz.edu

Jon Windsor: William.Windsor@cuanschutz.edu